Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) has entered into a termination agreement with Sorbie Bornholm LP and Sorbie Investments LLP to end a performance-based funding arrangement originally announced on July 29, 2026. The agreement will result in Sorbie returning an aggregate of 5,380,683 common shares for cancellation, comprising 2,761,635 shares held by Sorbie Bornholm and 2,619,048 shares held by Sorbie Investments.
The termination carries several implications for Onco-Innovations' capital structure and financial obligations. Sorbie Bornholm will receive the remaining credit support corresponding to C$4,444,444, while Onco-Innovations will relinquish its rights to further payments under the arrangement. Importantly, the transaction will not require an additional cash payment by the company. Additionally, Sorbie Investments will waive its right to receive 2.25 million additional common share purchase warrants, eliminating the company's obligation to issue those warrants.
The cancellation of over 5.38 million shares and the elimination of 2.25 million warrants represent a meaningful reduction in potential dilution for existing shareholders. By terminating the arrangement without a cash outlay, Onco-Innovations avoids future funding obligations tied to the performance-based structure while simplifying its share capital. The termination remains subject to customary closing conditions, including approval from Cboe Canada, and will take effect on a closing date agreed upon by the parties. For a detailed account, the full press release is available at https://ibn.fm/nx0ZV.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. The company holds an exclusive worldwide license to patented technology directed to the therapeutic inhibition of PNKP, a novel clinical target in DNA damage response. The funding termination allows the company to focus on advancing its oncology programs without the overhang of the previous arrangement.
For ongoing updates, the company's newsroom is accessible at https://ibn.fm/ONNVF. This article was disseminated on behalf of Onco-Innovations Limited and may include paid advertising. InvestorWire, the wire service behind this distribution, offers UNLIMITED Words on domestic releases and complimentary Press Release Enhancement, with follow-up coverage through the 50+ brands of the InvestorBrandNetwork. Full terms of use and disclaimers are available at http://ibn.fm/Disclaimer.


